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http://dx.doi.org/10.1016/j.gynor.2013.12.001Magnetic resonance imaging (MRI) showed a 75 × 64 × 55-mm
exophytic cervical mass with slight signal hyperintensity on T2-Introduction
Large cell neuroendocrine carcinoma (LCNEC) is an uncommon
histologic subtype of cervical cancerwith a prevalence of approximately
0.087% to 0.9% (Wang et al., 2009), and is an extremely aggressive
tumor with very poor prognosis. Knowledge of its distinct cytological
and histological features is necessary for early diagnosis and provision
of appropriate therapies. Multimodal treatments including surgery,
chemotherapy and radiotherapy are needed. However, because of the
low incidence, optimal therapy has yet to be determined, although
neoadjuvant chemotherapy (NAC) appears useful as a therapeutic tool
that may increase the resectability of these tumors.
Recently, the efﬁcacy of chemotherapywith irinotecanhydrochloride,
a topoisomerase I inhibitor, and cisplatin against metastatic small cell
lung cancer and cervical LCNEC after non-curative surgery was reported
(Noda et al., 2002; Tanimoto et al., 2012). NAC with irinotecan plus
nedaplatin was reported to be effective for bulky cervical squamous cell
carcinoma (SCC) (Yamaguchi et al., 2012). These reports led us to select
NAC with irinotecan plus cisplatin followed by radical hysterectomy forf Obstetrics and Gynecology, Faculty of
okato, Chuo-city, Yamanashi 409-3898,
M. Omori).
Elsevier Inc.Open access under CC BY-NC-ND license. ical features of a case of cervical LCNEC showing marked therapeutic
efﬁcacy with NAC using irinotecan plus cisplatin.Case report
A 51-year-old woman, gravida 3, para 3, presented with a history of
vaginal bleeding over several months. She had no history of medical or
surgical diseases. Gynecological examination revealed a bulky and
protruding tumor of the cervix, with involvement of the anterior fornix
of the vagina, but without parametrial invasion.
weighted imaging (T2WI), signal hyperintensity on diffusion-
weighted imaging, slight enhancement after injection of gadolinium
chelate, and evidence of invasion to the anterior fornix of the vagina,
but no evidence of invasion to the parametrium (Fig. 1). Computed
tomography (CT) and 18F-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET)/CT showed no apparent lymph node
involvement or metastatic disease. The tumor was classiﬁed as clinical
stage IIA2 (FIGO 2008).
Levels of carcinoembryonic antigen (CEA) were elevated, but other
tumor markers were within normal ranges: CEA, 13.0 ng/ml; carbohy-
drate antigen (CA) 125 12.5 U/ml; CA19-9, 11.82 U/ml; squamous cell
carcinoma antigen (SCC), 0.7 ng/ml; neuron-speciﬁc enolase (NSE),
13.87 ng/ml; and progastrin releasing peptide (proGRP), 23.2 pg/ml.
High-risk human papillomavirus (HPV) DNA testing yielded positive
results by hybrid capture 2 assay.Histological ﬁndings
Biopsy specimens showed a trabecular or solid growth pattern of the
atypical cells, with extensive geographic necrosis. The neoplastic cells
had hyperchromatic round to oval nuclei 3 to 5 times the size of
lymphocytes and moderately eosinophilic cytoplasms. The tumor was
mitotically active with a mitotic rate of more than 10 per 10 high-
powerﬁelds (HPFs) (Fig. 2). Immunohistochemistry revealedmoderately
positive results for synaptophysin and focally positive results for
chromogranin A. Consequently, this tumor was diagnosed as LCNEC.
The tumor showed diffuse and strong immunoreactivity for p16, but
was almost negative for p53 or CD56. HPV18 was identiﬁed by
polymerase chain reaction (PCR).
Fig. 1.MRI at initial diagnosis shows an exophytic cervical mass with evidence of invasion
to the anterior fornix of the vagina.
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Previous studies have recommended chemotherapy than radiation
therapy for LCNEC, because this tumor is more likely to have early
distant hematogenous or lymphatic metastasis (Embry et al., 2011;
Bermúdez et al., 2001). This bulky LCNEC led us to select chemotherapy
prior to surgery for the purpose of complete resection. We selected
combined therapy with irinotecan and cisplatin whose efﬁcacy and
safety for small cell lung cancer were reported by Noda et al. (2002).
The patient underwent NAC with intravenous irinotecan (60 mg/m2;
days 1, 8 and 15) and cisplatin (10 mg/m2; days 1–6). After two cycles
of chemotherapy, MRI showed a marked reduction in tumor size, to
37 × 45 × 34 mm. Serum CEA level was also decreased to 0.7 ng/ml.
The patient then underwent radical hysterectomy, bilateral
salpingo-oophorectomy and bilateral pelvic lymphadenectomy. Sec-
tioned surfaces of the tumor were yellowish and necrotic (Fig. 3-a).
Histologically, numerous foamy histiocytes were apparent in the
tumor, probably attributable to chemotherapy-induced apoptosis of
cancer cells. A few adenocarcinoma of the usual type coexisted withFig. 2.Histological ﬁndings of the biopsy specimen show tumor cells with hyperchromatic
nuclei 3 to 5 times the size of lymphocytes, and amitotic rate of more than 10 per 10HPFs
(H&E).LCNEC, with stromal invasion to 10 mm in depth (Fig. 3-b, c). Involve-
ments of the vaginal wall, parametrium and lymph nodes were not
observed, but those of vascular and lymphatic spaces were observed.
The surgical margins were negative. The postoperative diagnosis was
LCNEC with adenocarcinoma, ypT1b1N0M0.
Postoperatively, the patient convalesced well and received four
cycles of the same chemotherapy. The patient has received follow-up
by pelvic examination, cytology and tumor marker at every two
months, with CT scan at every six months. No evidence of recurrence
has been detected as of 21 months postoperatively.c
Fig. 3. a) Macroscopic ﬁndings of the surgically removed uterus show a yellowish and
necrotic tumor in the cervix. b) H&E. c) Immunohistochemical staining for synaptophysin.
b)Histologicalﬁndings of the surgical specimen show large cell neuroendocrine carcinoma
(LCNEC) (arrow head) coexisting with a few adenocarcinoma of the usual type (arrow),
and numerous histiocytes and apoptotic changes (asterisk). c) Tumor cells of LCNEC are
positive for synaptophysin.
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Neuroendocrine tumors of the uterine cervix are classiﬁed into four
categories: (typical) carcinoid; atypical carcinoid; LCNEC; and small cell
carcinoma (SmCC) (Albores-Saavedra et al., 1997). LCNECs have
frequently been histologically misdiagnosed, possibly due to the
occasional coexistence of other histological types. Thirty-three percent
of LCNECs were mixed type with SmCC, adenocarcinoma or SCC (Rekhi
et al., 2013).
The growth of LCNEC shows an insular, trabecular or solid pattern,
often with prominent peripheral palisading, rosette formation and
geographical tumor necrosis. Tumor cells are large and display vesicular
nuclei, prominent nucleoli, abundant cytoplasm, and eosinophilic
intracytoplasmic granules. Mitoses are frequent (more than 10 per 10
HPFs). The diagnosis of LCNEC must be conﬁrmed by an argyrophilic
reaction or immunopositive results for chromogranin or synaptophysin
(Albores-Saavedra et al., 1997; Gilks et al., 1997). However, positive
rates of LCNEC were 87% for chromogranin, 56% for synaptophysin, and
88% for at least one of chromogranin, synaptophysin, CD56, or NSE
(Rekhi et al., 2013).
LCNEC needs to be distinguished from atypical carcinoid, SmCC,
poorly differentiated SCC and adenocarcinoma. LCNECs often contain a
component of adenocarcinoma, SCC or SmCC (Rekhi et al., 2013);
thus, an adequately sized biopsy is needed for accurate diagnosis.
In terms of differential diagnosis, an atypical carcinoid shows a mi-
totic rate of less than 5 to 10 per 10 HPFs. SmCC shows small cells
with scant cytoplasm. SmCC, poorly differentiated SCC and adeno-
carcinoma lack intracytoplasmic eosinophilic granules and conspicuous
nucleoli.
In our case, HPV18 was detected by PCR, and intranuclear HPV
signals were observed in both LCNEC and adenocarcinoma lesions by
in situ hybridization (ISH). Overexpression of p16, which is regarded
as a surrogate marker of HPV-induced cancer, was observed in both
types of tumor cells. The presence of HPV has been demonstrated in
most reported cases of LCNEC, ranging from 53% to 100% (Siriaunkgul
et al., 2011), and associated with HPV16 and HPV18. Consequently,
currently available HPV vaccines may enable us to eliminate this tumor.
Embry et al. reported median overall survival rates of patients with
LCNEC as 19 months for stage I, 17 months for stage II, 3 months for
stage III, and 1.5 months for stage IV, and 70%of all patients experienced
disease relapses, with the most common sites of metastasis being the
liver and lung (Embry et al., 2011). Higher rates of lymph node involve-
ment of 40% to 86% have also been reported (Bermúdez et al., 2001).
Despite multiple treatment modalities, 47% of patients with even stage
I died of disease. Embry et al. conﬁrmed that younger age, earlier FIGO
stage, any surgery, speciﬁcally radical hysterectomy, chemotherapy at
anypoint during initial treatment, or speciﬁcally platinumchemotherapy
were associated with improved survival (Embry et al., 2011). Cervical
neuroendocrine carcinoma can cause lymphatic or hematogenous
metastases, even at an early stage, so chemotherapy is considered an
extremely effective therapy (Bermúdez et al., 2001).
Bermúdez et al. suggested that a therapeutic strategy combining
NAC, surgery and adjuvant chemotherapy could improve patient
survival with cervical neuroendocrine carcinoma. In tumors larger
than 4 cm in diameter, NAC was proposed for resectability, and consec-
utive surgery and postoperative chemotherapy were recommended,
because distant recurrence is seen in 64% of cases. In tumors less than
4 cm in diameter, patients with unfavorable prognostic factors such aslymphovascular space involvement, perineural inﬁltration, or deep
cervical invasion (N10 mm) were recommended to receive adjuvant
chemotherapy (Bermúdez et al., 2001).
The chemotherapy regimen including platinum has been considered
most effective. Bermúdez et al. recommended BEP therapy (bleomycin,
15 mg/m2/day, days 1–3; etoposide, 100 mg/m2/day, days 1–3; platinum,
75 mg/m2/day, day 1, with 21-day intervals) (Bermúdez et al., 2001).
Recently, Noda et al. have demonstrated that irinotecan plus cisplatin
(irinotecan 60 mg/m2, days 1, 8, and 15; cisplatin 60 mg/m2, day 1,
with 4-week cycles) was more effective than etoposide plus cisplatin
for the treatment of metastatic small cell carcinoma of the lung (Noda
et al., 2002). Tanimoto et al. reported the efﬁcacy of postoperative
irinotecan plus cisplatin (using the same regimen applied by Noda) for
cervical LCNEC (Tanimoto et al., 2012).
In our case, two cycles of NAC using irinotecan plus cisplatin were
extremely effective for bulky LCNEC tumor, and allowed complete
resection by radical hysterectomy. Appearance of numerous bizarre
giant cellswithmultiple nuclei ormacronuclei on cytological examination
after NAC, and the identiﬁcation of numerous histiocytes and apoptotic
changes on histological examination were considered as therapeutic
effects.
This case suggests that NAC with irinotecan plus cisplatin followed
by radical hysterectomy plus postoperative chemotherapy could be a
useful treatment option for bulky tumor of cervical LCNEC. Further
studies are necessary to obtain evidence of the most effective and
suitable treatment modalities for cervical LCNEC.
Conﬂict of interest statement
The authors declare no conﬂict of interest.
References
Albores-Saavedra, J., Gersell, D., Gilks, C.B., Henson, D.E., Lindberg, G., Santiago, H., et al.,
1997. Terminology of endocrine tumors of the uterine cervix: results of a workshop
sponsored by the College of American Pathologists and the National Cancer Institute.
Arch. Pathol. Lab. Med. 121, 34–39.
Bermúdez, A., Vighi, S., García, A., Sardi, J., 2001. Neuroendocrine cervical carcinoma: a
diagnostic and therapeutic challenge. Gynecol. Oncol. 82, 32–39.
Embry, J.R., Kelly, M.G., Post, M.D., Spillman, M.A., 2011. Large cell neuroendocrine
carcinoma of the cervix: prognostic factors and survival advantage with platinum
chemotherapy. Gynecol. Oncol. 120, 444–448.
Gilks, C.B., Young, R.H., Gersell, D.J., Clement, P.B., 1997. Large cell neuroendocrine
carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am. J. Surg.
Pathol. 21, 905–914.
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., et al., 2002.
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive
small-cell lung cancer. N. Engl. J. Med. 346, 85–91.
Rekhi, B., Patil, B., Deodhar, K.K., Maheshwari, A.A., Kerkar, R., Gupta, S., et al., 2013.
Spectrum of neuroendocrine carcinomas of the uterine cervix, including
histopathologic features, terminology, immunohistochemical proﬁle, and clinical
outcomes in a series of 50 cases from a single institution in India. Ann. Diagn. Pathol.
17, 1–9.
Siriaunkgul, S., Utaipat, U., Settakorn, J., Sukpan, K., Srisomboon, J., Khunamornpong, S.,
2011. HPV genotyping in neuroendocrine carcinoma of the uterine cervix in northern
Thailand. Int. J. Gynaecol. Obstet. 115, 175–179.
Tanimoto, H., Hamasaki, A., Akimoto, Y., Honda, H., Takao, Y., Okamoto, K., et al., 2012. A
case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully
treated by postoperative CPT-11 + CDDP chemotherapy after non-curative surgery.
Gan To Kagaku Ryoho 39, 1439–1441.
Wang, K.L., Wang, T.Y., Huang, Y.C., Lai, J.C., Chang, T.C., Yen, M.S., 2009. Human
papillomavirus type and clinical manifestation in seven cases of large-cell
neuroendocrine cervical carcinoma. J. Formos. Med. Assoc. 108, 428–432.
Yamaguchi, S., Nishimura, R., Yaegashi, N., Kiguchi, K., Sugiyama, T., Kita, T., et al.,
2012. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride
and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical
squamous cell carcinoma: Japanese. Oncol. Rep. 28, 487–493.
